ImmunityBio, Inc. @ImmunityBio

According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States. Through clinical research and collaboration, ImmunityBio is researching medications aiming to help those affected. Learn more about our research and clinical trials: immunitybio.com/non-small-cell…

Strong patient-centered care starts with listening. Today, patients, caregivers, patient leaders, and urologic experts came together at our first Annual Patient & Caregiver Conference to share perspectives, learn from one another, and explore ways to strengthen the patient voice. Through meaningful discussions on communication, health literacy, access to care, and collaboration, attendees identified opportunities to improve the experience of patients and families across the urologic community. Thank you to everyone who participated and contributed to a day of thoughtful conversation, connection, and shared learning.

keyboard_arrow_left Previous keyboard_arrow_right Next

We're excited to join the World Bladder Cancer Patient Forum 2026 in Hong Kong, bringing together voices from across the globe to advance bladder cancer care and advocacy. Today, ImmunityBio's Anjali Malhotra joined a panel on patient-centric clinical trial design, contributing to an important conversation about putting patients at the center of research. #BladderCancerForum26

What an honor to meet with President Erdogan today. Under his leadership Turkey will be the center of excellence for patients with cancer in the region.

Presidency of the Republic of Türkiye @trpresidency

2 weeks ago

President @RTErdogan, who is in New York for the 81st session of the United Nations General Assembly, received Dr. Patrick Soon-Shiong at the Turkish House.

12 39 225 1.2M 10

On World Lymphoma Awareness Day, we stand with the more than 1 million people worldwide living with lymphoma, including those facing Non-Hodgkin's Lymphoma, the most common form of this disease. At ImmunityBio, we are dedicated to advancing innovative immunotherapy approaches that are being studied for patients with Non-Hodgkin's Lymphoma. Today, we honor the patients, caregivers, and healthcare providers confronting lymphoma every day. Your strength drives our science.

ImmunityBio is expanding our team. We're seeking passionate professionals across research, clinical development, manufacturing, and corporate functions who share our commitment to advancing immunotherapy. Explore open roles: immunitybio.com/careers

September is Ovarian Cancer Awareness Month, a time to shine light on a disease that often goes undetected until its later stages. At ImmunityBio, researchers continue working to develop new treatment options for women facing ovarian cancer. Our work is driven by a commitment to develop investigational immunotherapies where options are limited. We honor the strength of patients and families navigating this journey, and we remain dedicated to advancing research that could transform outcomes. Learn more about our research: immunitybio.com/ovarian-cancer/

This past Sunday, we proudly participated in @GO2forLungCancr's first Annual 5K in Nashville. We joined patients, caregivers, and advocates with a shared commitment to improve outcomes for those affected by lung cancer. Thank you to everyone who helped make this event a success. Every step helped raise awareness, support the lung cancer community, and reinforce our commitment to advancing treatment options for patients. Together, we're moving the fight against lung cancer forward – one step at a time.

keyboard_arrow_left Previous keyboard_arrow_right Next

We're excited to welcome Dr. Jim Yong Kim, former President of the World Bank Group and global health leader, to ImmunityBio as Vice Chairman. Dr. Kim will join our newly formed Office of the Executive Chairman, where he'll focus on strengthening the company’s international and global relationships. His decades of experience at the intersection of medicine, public health, and development will be instrumental as we work to bring the benefits of immune activation to patients worldwide. Read more: immunitybio.com/immunitybio-ap…

ImmunityBio reports Q2 2026 net product revenue up 92% to a record $50.7 million, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoption among U.S. urologists and strong market access. First-half 2026 net product revenue totaled $94.8 million, up 121% compared with the first half of 2025. Access the full announcement: immunitybio.com/immunitybio-re…

Meaningful conversations about clinical trials and the future of bladder cancer happening at #BCANTT26. ImmunityBio is grateful to stand with @BladderCancerUS in their mission to support patients and caregivers every day. #BladderCancer

ImmunityBio has received marketing authorization in the United Arab Emirates for ANKTIVA® with BCG across two indications: BCG-unresponsive non-muscle invasive bladder cancer with CIS with or without papillary tumors and BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, and metastatic non-small cell lung cancer. This authorization expands our global regulatory footprint to 34 countries and marks another important step in broadening access to innovative immunotherapy options for patients worldwide. Learn more: immunitybio.com/immunitybio-re…

At ImmunityBio, we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. Learn more by visiting: immunitybio.com/glioblastoma/

Be part of something bigger. At ImmunityBio, we're developing innovative cancer therapies, and we need dedicated people like you to help us strive to improve patient outcomes. Explore opportunities to join our team: immunitybio.com/careers/

Our combination of highly experienced and talented people, deep scientific knowledge, and advanced research and manufacturing facilities enable us to invent, test, and market innovative therapies that address some of the greatest needs in medicine. Learn more about our focus on the development of novel treatments for advanced cancers and infectious diseases: immunitybio.com/about/

Early detection can be simple: pay attention to what feels different. Blood in the urine, a shift in frequency, discomfort that lingers; these signs may seem easy to dismiss, but recognizing them can expand the opportunity for timely evaluation and improved outcomes. ImmunityBio's relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients with bladder cancer.

We’re heading to ASCO 2026. We’re looking forward to joining researchers, clinicians, advocates, and industry partners united by a shared goal: improving outcomes for people impacted by cancer. Our team values the opportunity to collaborate and continue advancing patient-focused innovation alongside the broader oncology community. Visit us at booth #27131 to connect with the ImmunityBio team.

Behind every bladder cancer diagnosis is a person navigating uncertainty, complex decisions, and changes to their daily lifestyle. Organizations like @BladderCancerUS help ensure that affected individuals have access to information, support, and a community that understands what they're facing. Learn more about BCAN's resources for patients and caregivers: bcan.org

On Memorial Day, we pause to honor the bravery of those who stepped forward to serve. Your strength, service, and sacrifice will never be forgotten.

ImmunityBio announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of its bladder cancer therapy in combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ. Learn more: immunitybio.com/immunitybio-an…